77
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

, , , , , , , , , , & show all
Pages 2045-2056 | Published online: 02 Aug 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Ning Ma, Lei Zhang, Wufang Zhang, Yingying He, Chong Ye & Xin Li. (2023) Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review. Neuropsychiatric Disease and Treatment 19, pages 1987-2006.
Read now
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Tianmei Si, Jianmin Zhuo, Yu Feng, Huafei Lu, Di Hong & Lili Zhang. (2019) Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1685-1694.
Read now
Georgios Schoretsanitis, Edoardo Spina, Christoph Hiemke & Jose de Leon. (2018) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Review of Clinical Pharmacology 11:12, pages 1237-1253.
Read now

Articles from other publishers (3)

TTK Nguyen, C McDonald & B Hallahan. (2022) The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review. The European Journal of Psychiatry 36:3, pages 163-175.
Crossref
George T. Kannarkat, Stanley N. Caroff & James F. Morley. (2022) Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. Tremor and Other Hyperkinetic Movements 12:1.
Crossref
Pierre Chue, Vincent Agyapong & Adam Abba-Aji. 2018. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 99 119 .